Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

185
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
185
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline Lymphopenia Predicts Survival in ICI-Naïve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer Analysis.

Cancers·2026
Same author

Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions.

Biomolecules·2026
Same author

HER-2 Altered Early-Stage Non-Small Cell Lung Cancer Had Better Survival than Triple-Negative Disease.

Journal of clinical medicine·2026
Same author

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Comparison of subcutaneous checkpoint inhibitor immunotherapeutic agents.

Journal of thoracic disease·2026
Same author

Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung Cancer.

JAMA network open·2026

Related Experiment Video

Updated: Jun 10, 2025

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

6.8K

Systemic Therapy Options for Peritoneal Mesothelioma.

Tawee Tanvetyanon1, George R Simon1

  • 1Thoracic Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Journal of the National Comprehensive Cancer Network : JNCCN
|October 16, 2024
PubMed
Summary

Systemic therapies for peritoneal mesothelioma, though limited, are expanding. Current options include immunotherapy or chemotherapy, with newer agents showing promise for specific patient groups.

More Related Videos

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.1K
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.8K

Related Experiment Videos

Last Updated: Jun 10, 2025

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

6.8K
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.1K
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.8K

Area of Science:

  • Oncology
  • Medical Malignancies

Background:

  • Peritoneal mesothelioma is a rare cancer with limited specific clinical trials.
  • Treatment guidelines are often based on data from pleural mesothelioma.
  • Understanding effective systemic therapies is crucial for patient outcomes.

Purpose of the Study:

  • To review current systemic therapy options for peritoneal mesothelioma.
  • To highlight emerging treatment strategies and future research needs.

Main Methods:

  • Review of existing literature and clinical trial data for peritoneal mesothelioma.
  • Analysis of first-line, second-line, and later-line treatment recommendations.
  • Inclusion of data on novel therapeutic targets like ALK rearrangement.

Main Results:

  • First-line options include nivolumab/ipilimumab immunotherapy or pemetrexed/platinum chemotherapy.
  • Second-line treatment involves switching to the alternative first-line regimen.
  • Bevacizumab may be used off-label; third-line benefits are less defined, but single agents show activity.
  • ALK inhibitors show efficacy in rare pediatric/young adult cases with ALK rearrangement.

Conclusions:

  • Systemic therapy options for peritoneal mesothelioma are increasing.
  • Future prospective trials should incorporate more peritoneal mesothelioma patients.
  • Personalized medicine approaches, including targeted therapies, hold promise.